FluMist Shedding Studies Needed To More Clearly Define Transmission Rate
Executive Summary
MedImmune/Wyeth FluMist shedding studies are needed to more clearly define the probability of transmitting the influenza vaccine virus to a high-risk patient, FDA's Vaccine & Related Biological Products Advisory Committee recommended Dec. 17
You may also be interested in...
FluMist 60,000-Patient Phase IV Safety Study To Be Conducted With Kaiser
MedImmune will initiate a 60,000-patient, open-label safety study for FluMist by Sept. 30 as a Phase IV commitment following the June 17 approval of the intranasal flu vaccine
FluMist 60,000-Patient Phase IV Safety Study To Be Conducted With Kaiser
MedImmune will initiate a 60,000-patient, open-label safety study for FluMist by Sept. 30 as a Phase IV commitment following the June 17 approval of the intranasal flu vaccine
FluMist Comparison To Inactivated Vaccine Suggested By FDA Committee
MedImmune should conduct head-to-head comparisons of its live intranasal flu vaccine FluMist and the marketed trivalent inactivated vaccine, FDA's Vaccine & Related Biological Drug Products Advisory Committee suggested Dec. 17